News Lilly/Boehringer diabetes combos get cardio data boost Lilly/Boehringer gain further advantage in US diabetes market.
News Alnylam plunges after deaths in rare disease trial Biotech axes revusiran due to safety concerns.
News Patients may have quit statins after media row Coverage may have given "disproportional weight" to concerns over side effects.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
